FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313893014> ?p ?o ?g. }

• W4313893014 endingPage "2097" @default.
• W4313893014 startingPage "2087" @default.
• W4313893014 abstract "Idecabtagene vicleucel (ide-cel) is an autologous B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy approved for relapsed/refractory multiple myeloma (RRMM) on the basis of the phase II pivotal KarMMa trial, which demonstrated best overall and ≥ complete response rates of 73% and 33%, respectively. We report clinical outcomes with standard-of-care (SOC) ide-cel under the commercial Food and Drug Administration label.Data were retrospectively collected from patients with RRMM who underwent leukapheresis as of February 28, 2022, at 11 US institutions with intent to receive SOC ide-cel. Toxicities were graded per American Society for Transplantation and Cellular Therapy guidelines and managed according to each institution's policies. Responses were graded on the basis of the International Myeloma Working Group response criteria.One hundred fifty-nine of 196 leukapheresed patients received ide-cel by data cutoff. One hundred twenty (75%) infused patients would have been ineligible for participation in the KarMMa clinical trial because of comorbidities at the time of leukapheresis. Any grade and grade ≥ 3 cytokine release syndrome and neurotoxicity occurred in 82/3% and 18/6%, respectively. Best overall and ≥ complete response rates were 84% and 42%, respectively. At a median follow-up of 6.1 months from chimeric antigen receptor T infusion, the median progression-free survival was 8.5 months (95% CI, 6.5 to not reached) and the median overall survival was 12.5 months (95% CI, 11.3 to not reached). Patients with previous exposure to B-cell maturation antigen-targeted therapy, high-risk cytogenetics, Eastern Cooperative Oncology Group performance status ≥ 2 at lymphodepletion, and younger age had inferior progression-free survival on multivariable analysis.The safety and efficacy of ide-cel in patients with RRMM in the SOC setting were comparable with those in the phase II pivotal KarMMa trial despite most patients (75%) not meeting trial eligibility criteria." @default.
• W4313893014 created "2023-01-10" @default.
• W4313893014 creator A5001877903 @default.
• W4313893014 creator A5002558709 @default.
• W4313893014 creator A5004973468 @default.
• W4313893014 creator A5005843572 @default.
• W4313893014 creator A5008366988 @default.
• W4313893014 creator A5016470756 @default.
• W4313893014 creator A5017390274 @default.
• W4313893014 creator A5021394406 @default.
• W4313893014 creator A5023064593 @default.
• W4313893014 creator A5027546805 @default.
• W4313893014 creator A5039680248 @default.
• W4313893014 creator A5042487436 @default.
• W4313893014 creator A5047819225 @default.
• W4313893014 creator A5052064208 @default.
• W4313893014 creator A5053731124 @default.
• W4313893014 creator A5054360080 @default.
• W4313893014 creator A5060313982 @default.
• W4313893014 creator A5069437923 @default.
• W4313893014 creator A5071438752 @default.
• W4313893014 creator A5074144760 @default.
• W4313893014 creator A5077110117 @default.
• W4313893014 creator A5080882830 @default.
• W4313893014 creator A5081601392 @default.
• W4313893014 creator A5082532520 @default.
• W4313893014 creator A5087799564 @default.
• W4313893014 date "2023-04-10" @default.
• W4313893014 modified "2023-10-16" @default.
• W4313893014 title "Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium" @default.
• W4313893014 cites W2486629951 @default.
• W4313893014 cites W2494994085 @default.
• W4313893014 cites W2905654445 @default.
• W4313893014 cites W2921533600 @default.
• W4313893014 cites W2923396001 @default.
• W4313893014 cites W2943335541 @default.
• W4313893014 cites W2969931905 @default.
• W4313893014 cites W2979807505 @default.
• W4313893014 cites W2995934717 @default.
• W4313893014 cites W3005994291 @default.
• W4313893014 cites W3094757324 @default.
• W4313893014 cites W3097084286 @default.
• W4313893014 cites W3097418661 @default.
• W4313893014 cites W3097902874 @default.
• W4313893014 cites W3133229959 @default.
• W4313893014 cites W3137335748 @default.
• W4313893014 cites W3176532045 @default.
• W4313893014 cites W3183441818 @default.
• W4313893014 cites W3188071931 @default.
• W4313893014 cites W3212997432 @default.
• W4313893014 cites W3214045426 @default.
• W4313893014 cites W3214467627 @default.
• W4313893014 cites W3217436200 @default.
• W4313893014 cites W4200108738 @default.
• W4313893014 cites W4281714381 @default.
• W4313893014 doi "https://doi.org/10.1200/jco.22.01365" @default.
• W4313893014 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36623248" @default.
• W4313893014 hasPublicationYear "2023" @default.
• W4313893014 type Work @default.
• W4313893014 citedByCount "30" @default.
• W4313893014 countsByYear W43138930142023 @default.
• W4313893014 crossrefType "journal-article" @default.
• W4313893014 hasAuthorship W4313893014A5001877903 @default.
• W4313893014 hasAuthorship W4313893014A5002558709 @default.
• W4313893014 hasAuthorship W4313893014A5004973468 @default.
• W4313893014 hasAuthorship W4313893014A5005843572 @default.
• W4313893014 hasAuthorship W4313893014A5008366988 @default.
• W4313893014 hasAuthorship W4313893014A5016470756 @default.
• W4313893014 hasAuthorship W4313893014A5017390274 @default.
• W4313893014 hasAuthorship W4313893014A5021394406 @default.
• W4313893014 hasAuthorship W4313893014A5023064593 @default.
• W4313893014 hasAuthorship W4313893014A5027546805 @default.
• W4313893014 hasAuthorship W4313893014A5039680248 @default.
• W4313893014 hasAuthorship W4313893014A5042487436 @default.
• W4313893014 hasAuthorship W4313893014A5047819225 @default.
• W4313893014 hasAuthorship W4313893014A5052064208 @default.
• W4313893014 hasAuthorship W4313893014A5053731124 @default.
• W4313893014 hasAuthorship W4313893014A5054360080 @default.
• W4313893014 hasAuthorship W4313893014A5060313982 @default.
• W4313893014 hasAuthorship W4313893014A5069437923 @default.
• W4313893014 hasAuthorship W4313893014A5071438752 @default.
• W4313893014 hasAuthorship W4313893014A5074144760 @default.
• W4313893014 hasAuthorship W4313893014A5077110117 @default.
• W4313893014 hasAuthorship W4313893014A5080882830 @default.
• W4313893014 hasAuthorship W4313893014A5081601392 @default.
• W4313893014 hasAuthorship W4313893014A5082532520 @default.
• W4313893014 hasAuthorship W4313893014A5087799564 @default.
• W4313893014 hasConcept C10205521 @default.
• W4313893014 hasConcept C121332964 @default.
• W4313893014 hasConcept C121608353 @default.
• W4313893014 hasConcept C126322002 @default.
• W4313893014 hasConcept C141071460 @default.
• W4313893014 hasConcept C142424586 @default.
• W4313893014 hasConcept C143998085 @default.
• W4313893014 hasConcept C203014093 @default.
• W4313893014 hasConcept C2776364478 @default.
• W4313893014 hasConcept C2776694085 @default.
• W4313893014 hasConcept C2777063308 @default.

• next